Planning adjuvant therapy for melanoma

The melanoma may have been fully removed from the place where it was found, yet its pathology can indicate a meaningful chance of cells having travelled beyond that area. Systemic medicine circulates through the body to address that possibility. Some patients instead proceed with surveillance after discussing likely benefit, toxicity and personal priorities.

Planning starts with accurate staging. Tumour thickness and ulceration, whether nearby lymph nodes contained melanoma, surgical findings and relevant imaging help define the situation. Testing the melanoma for certain gene changes can show whether targeted tablets are an option. Immunotherapy may be offered without that particular tumour change because it works through immune activation.

Each route has a different pattern of side effects and monitoring. Immune-related problems can affect organs such as the bowel, liver, lungs, hormone glands, skin or nervous system. Targeted medicines can cause fever, rash and other systemic symptoms. Your oncology team should explain the specific medicine rather than treating these possibilities as interchangeable.

Before therapy begins, confirm the name of the medicine, how to take or receive it, and which baseline tests are required. Share every prescription, over-the-counter product and supplement. Discuss autoimmune conditions, heart or lung problems, infection, transplantation, fertility goals and contraception because these details can alter planning.

Keep a simple symptom diary that includes temperature when you feel feverish, bowel changes, rashes, breathing symptoms and missed doses. Use the oncology contact number for advice before changing or stopping treatment. Continue the scheduled melanoma skin examinations and imaging even when you feel well, because follow-up looks for both recurrence and delayed treatment effects.

Call the cancer team without delay for persistent fever, repeated vomiting, significant diarrhoea, dark urine, yellow skin or eyes, a new troublesome cough, breathlessness, severe rash, unusual drowsiness, intense headache, visual disturbance or new muscle weakness. These symptoms can have several causes, but treatment-related inflammation or infection needs timely assessment.

Get emergency help for a seizure, loss of consciousness, sudden speech difficulty, abrupt one-sided weakness, chest pain or severe breathing trouble. Do not judge urgency by whether a symptom seems connected to melanoma; follow the emergency guidance supplied by your treatment centre.

Ask which staging and pathology details make you eligible, whether tumour testing changes the choices, and how each option fits your other health conditions. Request clear instructions for missed doses, travel, vaccinations and after-hours symptoms. You may also want to discuss how the team will judge tolerability, when a pause is considered, and how dermatology and oncology appointments will be coordinated.